Detalhe da pesquisa
1.
First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial.
Lancet
; 397(10272): 375-386, 2021 01 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-33485464
2.
First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in advanced non-small cell lung cancer: a subanalysis of Asian patients in CheckMate 9LA.
Int J Clin Oncol
; 27(4): 695-706, 2022 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-35182247
3.
First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial.
Lancet Oncol
; 22(2): 198-211, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33476593
4.
Impact of elotuzumab treatment on pain and health-related quality of life in patients with relapsed or refractory multiple myeloma: results from the ELOQUENT-2 study.
Ann Hematol
; 97(12): 2455-2463, 2018 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-30178193
5.
Heterogeneity of treatment effects in malignant pleural mesothelioma - Authors' reply.
Lancet
; 398(10297): 302, 2021 07 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-34303436
6.
Safety profile of nivolumab administered as 30-min infusion: analysis of data from CheckMate 153.
Cancer Chemother Pharmacol
; 81(4): 679-686, 2018 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-29442139
7.
Management of chronic myeloid leukaemia in clinical practice in France: results of the French subset of patients from the UNIC study.
Curr Med Res Opin
; 26(2): 307-17, 2010 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-19961284